News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 18/09/2026 +03			5-day change	1st Jan Change
508.34 ^USD	-1.55%		-1.38%	+12.13%

09-14	Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:00 AM
09-11	Vertex Pharmaceuticals Incorporated Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM

All News

Mentions Relevance

09-15	Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain	BU
09-14	Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:00 AM
09-11	Vertex Pharmaceuticals Incorporated Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM
09-10	Vertex Pharmaceuticals Incorporated Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 04:30 PM
09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
09-01	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027	CI
09-01	Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027	CI
09-01	Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes	DJ
09-01	Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition	MT
09-01	Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team	BU
08-26	Vertex to Participate in Upcoming September Investor Conferences	BU
08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
08-11	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
08-10	Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint	DJ
08-10	Sionna scraps genetic disorder drug program after trial setback; shares tank	RE
08-05	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
08-05	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)	PU
08-04	Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced on May 19, 2025.	CI
08-04	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
08-04	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
08-04	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
08-04	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
08-04	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
08-04	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT